

# 1 High prevalence of putative invasive pulmonary aspergillosis in critically ill 2 COVID-19 patients

3  
4 Alexandre Alanio,<sup>1,2,3,\*</sup> Sarah Dellière,<sup>1,2,3</sup> Sofiane Fodil,<sup>2,4</sup> Stéphane Bretagne,<sup>1,2,3</sup> Bruno  
5 Mégarbane<sup>2,5,6</sup>

6  
7 <sup>1</sup> Laboratoire de Parasitologie-Mycologie, AP-HP, Groupe Hospitalier Saint-Louis-Lariboisière-  
8 Fernand-Widal, Paris, France

9 <sup>2</sup> Université de Paris, Paris, France

10 <sup>3</sup> Institut Pasteur, CNRS, Unité de Mycologie Moléculaire, Centre National de Référence  
11 Mycoses Invasives et Antifongiques, URA3012, Paris, France

12 <sup>4</sup> Médecine Intensive Réanimation, AP-HP, Groupe Hospitalier Saint-Louis-Lariboisière-  
13 Fernand-Widal, Paris, France

14 <sup>5</sup> Réanimation Médicale et Toxicologique, AP-HP, Groupe Hospitalier Saint-Louis-  
15 Lariboisière-Fernand-Widal, Paris, France

16 <sup>6</sup> INSERM UMRS1144, Paris, France

17  
18 \* Corresponding author: Dr Alexandre Alanio. Saint Louis Hospital, 1 avenue Claude  
19 Vellefaux, 75475 Paris CEDEX 10, alexandre.alanio@aphp.fr.

## 21 Abstract:

22 We are currently facing a frightening increase in COVID-19 patients admitted to the ICU.  
23 Aiming at screening for fungal secondary pneumonia, we collected the data of our first 27  
24 ICU patients, who underwent bronchoalveolar lavage or bronchial aspirates. We classified  
25 the patients based on the recently published study on invasive aspergillosis in influenza  
26 patients (Schauwvlinghe et al., 2018.) and found 33% of our COVID-19 patients with putative  
27 invasive pulmonary aspergillosis. Observing such a high prevalence in COVID-infected  
28 patients was somehow unexpected since the 30% prevalence of invasive aspergillosis in  
29 influenza patients has been attributed to the action of oseltamivir on anti-Aspergillus  
30 immunity. Almost all critically ill COVID-19 patients develop ARDS and are likely to receive  
31 high-dose steroids or immunomodulatory therapies to prevent worsening as suggested by  
32 reports from China. In the COVID-19 patients with putative invasive aspergillosis, antifungal  
33 prophylactic therapy may be questioned to avoid increased lung inflammation that may  
34 compromise the outcome. This issue remains to be addressed in future clinical trials. We are  
35 strongly convinced that testing deep lung specimens for Aspergillus in severe COVID-19

36 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 About 5% of coronavirus disease 2019 (COVID-19) patients require intensive care unit (ICU)  
38 management.<sup>1</sup> In the ICU, these patients are at high risk of developing secondary infections  
39 including invasive pulmonary aspergillosis (IPA).<sup>2</sup> First reported with H1N1 influenza, IPA  
40 represents a frequent (20-30%) and early-onset complication (median, 3 days post-ICU  
41 admission) in critically ill influenza patients leading to enhanced illness severity and mortality  
42 rate (40-60%).<sup>3,4</sup> Interestingly, most influenza-associated IPA cases were observed in non-  
43 immunocompromised patients, thus questioning the applicability of the EORTC-MSG  
44 consensus criteria used largely to define aspergillosis in immunocompromised patients.<sup>5</sup>  
45 Therefore, in the ICU patients without the usual risk factors, a clinical algorithm to  
46 discriminate *Aspergillus* colonization from putative IPA was recently developed based on  
47 mycological criteria combining visualization and culture of *Aspergillus* from respiratory  
48 specimens and galactomannan detection in the bronchoalveolar lavage (BAL) and serum.<sup>4,6</sup>  
49 Paralleling what has been reported in influenza patients, we designed this prospective  
50 observational bi-center study to investigate the risk of IPA in critically ill COVID-19 patients,  
51 especially since these patients were likely to receive immunomodulatory therapies. The  
52 patients were classified using the influenza-associated IPA criteria in the ICU<sup>4</sup> completed  
53 with beta-D-glucan measurement and quantitative real-time PCR (qPCR) in BAL. Putative IPA  
54 was considered if one of the following conditions was met, i.e. 1- presence of *Aspergillus*  
55 *fumigatus* in culture; 2- BAL galactomannan index >0.8 AND beta-D-glucan >80 pg/mL; 3-  
56 *Aspergillus fumigatus* qPCR with quantification cycle <35 in pulmonary specimens;<sup>7</sup> and/or  
57 4- serum beta-D-glucan >80pg/mL AND serum galactomannan index >0.5. Of note, direct  
58 examination of respiratory specimens was not performed to avoid operator contamination.  
59 Twenty-seven successive mechanically ventilated COVID-19 patients with pneumonia  
60 admitted between March 16<sup>th</sup> and 28<sup>th</sup> to our two ICUs were included (Table 1). Respiratory  
61 specimens (20 BALs and 7 bronchial aspirations) were obtained on day 3 [1-6] post-  
62 intubation. Putative IPA was diagnosed in 9/27 patients (33%) including six patients  
63 validating  $\geq 2$  mycological criteria and three patients with only *Aspergillus fumigatus*  
64 identification in the respiratory specimen culture. History of hypertension was significantly  
65 more frequently reported in the patients with putative IPA than patients without  
66 aspergillosis ( $p=0.04$ ). No other significant differences were observed in terms of age,  
67 invasive aspergillosis EORTC-MSG risk factors, time between onset of symptoms and  
68 intubation and times between onset of symptoms or intubation and *Aspergillus* respiratory

69 specimen collection, ARDS severity, clinical and laboratory data, non-COVID CT-scan images  
70 and steroid administration. No other immunosuppressant drug was administered in the ICU.  
71 Specific anti-*Aspergillus* therapy was initiated in only one of the nine patients with putative  
72 IPA. In this patient initially receiving caspofungin to treat concomitant invasive blood  
73 *Candida glabrata* infection, antifungal treatment was switched to voriconazole. No  
74 significant increase in fatality rate was observed in the patients with putative IPA (3/9 versus  
75 3/18,  $p=0.4$ ), although so far, 2/9 and 8/18 patients are still intubated in each group,  
76 respectively.

77 Here we found putative IPA in almost one third of our successive critically ill COVID-19  
78 patients, at a similar rate to what has been observed in influenza patients.<sup>3,4</sup> Interestingly,  
79 when respiratory specimens were positive for *Aspergillus*, serum galactomannan was  
80 negative. One case had positive serum beta-D-glucan and galactomannan without  
81 *Aspergillus* detection in the BAL. Our findings strongly suggest that mechanically ventilated  
82 COVID-19 patients should be systematically screened for *Aspergillus* infection markers.  
83 Three of our cases had *Aspergillus fumigatus* culture with no positive qPCR detection or  
84 galactomannan antigen in the BAL. Interestingly, not considering positive culture alone as a  
85 diagnostic criterion, by contrast to what is currently accepted,<sup>4,6</sup> would have resulted in  
86 underestimating the frequency of putative IPA (22% rather than 33% in our study).

87 Despite similar IPA rates in critically ill COVID-19 and influenza patients, the contribution of  
88 *Aspergillus* to the patient presentation in each illnesses may be different. Here, none of our  
89 nine putative IPA patients except one received anti-*Aspergillus* treatment. In the treated  
90 patient, antifungal treatment was adapted to cover both candida and *Aspergillus* infections.  
91 In the IPA group, the three fatalities were not related to aspergillosis but to bacterial septic  
92 shock complicated by multiorgan failure.

93 Finally, although oseltamivir-induced inhibition of the host neuraminidase activity has been  
94 suggested as a possible molecular mechanism leading to anti-aspergillus protective  
95 immunity decrease in influenza patients, the exact reasons for increased vulnerability of the  
96 COVID-19 patient to *Aspergillus* remain to be determined as well as the *Aspergillus*  
97 contribution to COVID-19-related lung inflammation.

98

#### 99 **Conflict of interest**

100 The authors declare no conflict of interest

101 **Ethics**

102 This study was part of the French COVID-19 cohort registry conducted by the REACTing  
103 consortium and directed by INSERM and ISARIC. Our institutional ethics committee  
104 approved the study (N°, IDRCB, 2020-A00256-33; CPP, 11-20 20.02.04.68737). When  
105 possible, signed informed consent was obtained from the patients or the next of kin.

106

107 **References**

108 1- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus  
109 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the  
110 Chinese Center for Disease Control and Prevention. *JAMA* 2020.  
111 DOI:10.1001/jama.2020.2648.

112 2- Lescure F-X, Bouadma L, Nguyen D, *et al.* Clinical and virological data of the first cases of  
113 COVID-19 in Europe: a case series. *Lancet Infect Dis* 2020. DOI:10.1016/s1473-  
114 3099(20)30200-0.

115 3- Wauters J, Baar I, Meersseman P, *et al.* Invasive pulmonary aspergillosis is a frequent  
116 complication of critically ill H1N1 patients: a retrospective study. *Intens Care Med* 2012; **38**:  
117 1761–8.

118 4- Schauwvlieghe AFAD, Rijnders BJA, Philips N, *et al.* Invasive aspergillosis in patients  
119 admitted to the intensive care unit with severe influenza: a retrospective cohort study.  
120 *Lancet Respir Medicine* 2018; **6**: 782–92.

121 5- Donnelly JP, Chen SC, Kauffman CA, *et al.* Revision and Update of the Consensus  
122 Definitions of Invasive Fungal Disease From the European Organization for Research and  
123 Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin*  
124 *Infect Dis Official Publ Infect Dis Soc Am* 2019. DOI:10.1093/cid/ciz1008.

125 6- Blot SI, Taccone FS, Abeele A-MV den, *et al.* A Clinical Algorithm to Diagnose Invasive  
126 Pulmonary Aspergillosis in Critically Ill Patients. *Am J Resp Crit Care* 2012; **186**: 56–64.

127 7- Alanio A, Menotti J, Gits-Muselli M, *et al.* Circulating *Aspergillus fumigatus* DNA Is  
128 Quantitatively Correlated to Galactomannan in Serum. *Front Microbiol* 2017; **8**: 2040.

129

130 **Table 1.** Characteristics of 27 critically ill COVID-19 patients according to the clinical  
 131 classification of aspergillosis. Comparisons were performed using Chi-2 or Mann-Whitney  
 132 tests, as appropriate.

Parameters	Putative aspergillosis (n=9)	No aspergillosis (n=18)	p
Age (years)	63	63	1.0
Sex ratio (M/F)	1.3	2.6	0.4
Diabetes, %	33	33	1.0
Hypertension, %	78	33	<b>0.04</b>
Obesity, %	33	17	0.4
Ischemic heart disease, %	22	33	0.7
Aspergillosis host factors, %†	22	17	1.0
Time from symptoms start to tracheal intubation (days)	7 [3-10]	8 [5-13]	0.2
Time from tracheal intubation to <i>Aspergillus</i> pulmonary specimen (days)	6 [1-11]	2 [0-10]	0.1
Time from symptoms start to <i>Aspergillus</i> pulmonary specimen (days)	12 [7-15]	11 [5-21]	0.7
Viral load, (cycles)	24 [17-37]	27 [15-34]	1.0
PaO <sub>2</sub> /FiO <sub>2</sub> (mmHg)	167 [88-290]	163 [42-480]	0.8
Non-COVID CT scan signs, %	67	43	1.0
BAL macrophages, % (N=20)	26 [8-55]	34 [4-49]	0.8
BAL neutrophils, % (N=20)	47 [10-82]	30 [13-87]	1.0
BAL lymphocytes, % (N=20)	12 [6-48]	24 [1-53]	0.6
Vasopressors, %	89	67	0.4
Renal replacement, %	30	22	0.7
Steroid administration in the ICU, %††	67	72	1.0
Deaths, %	33	17	0.4

133 †based on EORTC MSG criteria for invasive aspergillosis, including steroids (n=3) and haematological  
 134 malignancies (n=2); ††Steroid regimen, dexamethasone intravenous dose of 20 mg once daily from day 1 to  
 135 day 5, followed by 10 mg once daily from day 6 to day 10; BAL, bronchoalveolar lavage; ICU, intensive care unit;  
 136 CT scan, computerized tomography scanner.